Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.10 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (retinal amacrine cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: pascolizumab, romilkimab | 0.81 |
| trials ClinicalTrials.gov | 9 Parkinson's trials, 1 stopped | 0.91 |
| literature PubMed | 106 Parkinson's papers of 57,977 | 0.39 |
| pathways Reactome | 5 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 2742
Sealed predictions
- IL4 in dopamine neurons, braak+0.45 (p 0.219) → -0.60 (p 0.086)receipt 2749
Swarm cases
receipt 2749: IL4 in dopamine neurons, braak
- power
- full sample -0.25 (p 0.310, n 18), 95% CI -0.64 to +0.24. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.30 (p 0.232, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.40 (p 0.097, n 18). could be the mix.
- skeptic
- leave-one-out range -0.40 to -0.16, sign flips 0; without severely affected donors -0.25 (p 0.310, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for IL4 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts